))
Episode 13
Manage episode 407524159 series 3562806
Content provided by Jennifer Brockman and Dr. Don Stader. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jennifer Brockman and Dr. Don Stader or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode Dr. Stader and Dr. Bradley summarize and offer key insights for the following Coaches Top 5 picks, discussing the new opioid antagonist nalmefene, the 6% increase in buprenorphine prescribing associated with the x-waiver repeal, brain signals associated with chronic pain, and more!
Scientists Find Brain Signals of Chronic Pain, Published in the NY Times, May 2023
Analgesic efficacy of an opioid-free postoperative pain management strategy versus a conventional opioid-based strategy following open major hepatectomy: an open-label, randomised, controlled, non-inferiority trial- Published in the Lancet, August 2023
Stronger, longer, better opioid antagonists? Nalmefene is NOT a naloxone replacement Published in the International Journal on Drug Policy, January 2024
The misguided reason why providers aren’t prescribing more buprenorphine for opioid use disorder Published by STAT, January 2024
Effectiveness of an unsupervised online yoga program on pain and function in people with knee osteoarthritis. A randomized clinical trial. Published in the Annals of Internal Medicine, September 2022
32 episodes
Share
